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Abstract We have analysed the expression of the genes 
encoding transcription factors involved in c-fos transcriptional 
regulation, i.e. the serum response factor (SRF) and the ETS- 
related proteins ELK-1 and SAP-I, in a variety of human cell 
lines. RNA was determined by Northern blot analysis, and 
proteins were detected on Western blots: the two analyses gave 
essentially identical results. SRF was expressed at similar levels 
in all cell lines tested. In contrast, SAP-1 and ELK-! expression 
varied from one cell line to another. Interestingly, in any given 
cell line, high levels of one protein were accompanied by low 
levels of the other. Similar results were obtained by electro- 
mobility shift assays (EMSA), using antibodies directed against 
the proteins. Thus, our data raise the possibility of a coordinated 
regulation of the expression of these two Ets genes, at both RNA 
and protein levels. 
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1. Introduction 
The c-fos proto-oncogene is an immediate arly gene which 
is transiently transcribed in response to growth factors and 
other stimuli [1]. c-fos transcriptional ctivation by growth 
factors seems to be universal. In all cell types tested, from 
fibroblasts [2] to lymphocytes [3] and nerve cells [4], the serum 
responsive lement (SRE), a DNA element in the c-fos pro- 
moter, is responsible for most c-fos responses. Several proteins 
bind to the SRE [5], including p67 sRF, which recognizes a
CArG box in the center of the element [6,7], and p62 Tcr, 
which binds to an Ets box located in the SRE in close proxi- 
mity to the CArG box [8,9]. While binding of p62 TcF is weak, 
p62 TcF recognized the SRE with a high affinity in the presence 
of SRF, allowing the formation of a ternary complex. P62 TcF 
has been shown to be highly related to the ETS protein ELK- 
1 [10]. Proteins from another sub-group in the ETS family, the 
SAP-1 proteins, are also able to form a ternary complex and 
display a TCF activity [11]. It has been shown that there are 
two separate signalling pathways for the activation of distinct 
TCFs: one dependent on Ras and MAP kinase and converg- 
ing on TCF/ELK-1, and the other targeting TCF/SAP-1 in- 
dependently of Ras and MAP Kinase, suggesting that these 
two TCFs do not share exactly the same function in the cell. 
Some external activating signals are mediated through TCF 
phosphorylation [10,12], whereas other signals go through the 
SRF protein itself [13,14]. 
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The pattern of SRF gene expression has been described in 
the human cell line HeLa [15] and in murine myoblastic ell 
lines [16]. SAP-1 and ELK-1 transcripts have been analyzed in 
human and mouse tissues with discordant results: Giovane et 
al. [17] have reported distinct tissue specificities for murine 
ELK-1 and SAP-la, SAP-la being expressed at a high level 
in lung and liver, whereas ELK-1 was strongly expressed in 
heart and brain but undetectable in lung. In contrast, Rao et 
al. [18] showed that, in mouse embryo, ELK-1 was only ex- 
pressed in lung and liver, its expression in adult tissues being 
restricted to testis, lung and, to a lesser extent, brain. Finally, 
SAP-la and ELK-1 have more recently been described as 
being expressed at similar levels in a great variety of human 
tissues [19]. At the protein level, Pingoud et al. [20] did not 
detect any SAP-1 in ternary complex formed by nuclear pro- 
teins of HeLa cells, and ELK-1 appeared to be responsible for 
most of the TCF activity in these cells. 
Here, we have used Northern and Western analyses, fol- 
lowed by mRNA and protein quantification, to study the ex- 
pression of SRF, SAP-la and ELK-1 in a variety of human 
cell lines from distinct issue origins. Our results indicate (1) 
that SRF is expressed at similar levels in all cell lines tested, 
whereas SAP-la and ELK-1 mRNA and protein levels are less 
homogeneous, and (2) that high levels of one TCF transcript 
and protein are accompanied by low levels of the other. These 
results were confirmed using EMSA analysis. 
2. Materials and methods 
2.1. Cell lines 
Human cell lines used in this study included HeLa (a cervical car- 
cinoma), Saos-2 (an osteosarcoma), IARC-EW17 (a Ewing sarcoma), 
K526 (an erythroleukemia), E418 (a lymphoblastoid EBV-positive B 
cell line), Ramos and BL2 cells (an EBV-positive and an EBV-nega- 
tive Burkitt's lymphoma), and Jurkat (an acute T cell leukemia). They 
were maintained in RPMI 1640 or DMEM medium containing 10 or 
15 % FCS. 
2.2. Northern analysis 
Total RNA was isolated by the acid guanidinium thiocyanate/ce- 
sium chloride method [21]. RNA (30 ~tg/lane) was subjected to elec- 
trophoresis in agarose containing 1.2% formaldehyde and transferred 
onto nitrocellulose [22]. Hybridization was performed at 42°C in 
5 ×SSPE, 0.1% SDS, 5xDenhardt and 100 p.g salmon sperm DNA, 
in the presence of 50% formamide. The following probes were pre- 
pared and labelled, using the Prime-a-gene system kit (Promega) and 
[a-a2P]dCTP: 
SRF, a 450 bp HindIII-XhoI fragment from human SRF cDNA 
corresponding to the amino-terminal portion [15]. 
FLI-1, a 1410 bp fragment encompassing the entire ORF of the 
human FLI-1 cDNA: RT-PCR was performed from IARC-EW11 (a 
Ewing Sarcoma cell line) total RNA using the following primers: 
5'ATTCGCTCTAGAATGTGTGGAATATTGGGG3' 
5'ATTGCCTCTAGAAGCTTCTAGTAGTAGCTG3'. The PCR 
product corresponding to FLI-1 cDNA was cloned in pUC 18. 
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SAP-la, a 185 bp HindlII 3' fragment from human SAP-1 eDNA 
[11]. 
ELK-I, a 516 bp ApaI 3' fragment from human ELK-1 cDNA [23]. 
After overnight hybridization, blots were washed in 2×SSPE, 0.1% 
SDS (45°C, 15 min) followed by washing in 1 ×SSPE, 0.1% SDS 
(65°C, 20 min) and exposed to X-ray films for various periods of time. 
Northern blot signals were quantified using a Bas 1000 Phospho- 
imager-(Mac Bas V1.01, Fuji) and 18S RNA levels as a control. 
2.3. Nuclear extracts 
Nuclear extracts were prepared according to the method escribed 
by Andrews and Failer [24]. 
2.4. Western blot analysis 
Nuclear proteins (10 ~tg/lane) were loaded onto 7.5% SDS-PAGE 
gels (acrylamide 100:1) prior to electrophoretic transfer onto a PVDF 
nitrocellulose membrane (Millipore). The blots were blocked with 10% 
dry milk and incubated with a rabbit antiserum directed against SRF, 
ELK-I, or ELK-1 and SAP-1. Anti-SRF and anti-SAP-I/ELK-1 anti- 
bodies were raised against GST-fusion proteins prepared in bacteria. 
The blots were subsequently incubated for I h at room temperature 
with antirabbit horseradish peroxidase-conjugated ntibodies, prior to 
exposure to the ECL substrate. Western blot signals were measured 
by scanning of the autoradiogram followed by quantification using 
Fuji Mac bas software. 
2.5. Electromobility shift assays 
EMSA were performed using 6 ~tg of protein and a radiolabeled 
wtETS SRE probe as previously described [25]. Samples were incu- 
bated for 15 rain at room temperature with either an anti-SAP-la goat 
polyclonal antibody directed against the C-terminal region of SAP-Ia 
(aa 409-428) (Santa Cruz), or an anti-ELK-1 goat polyclonal anti- 
body directed against he C-terminal region of ELK-1 (aa 407-428) 
(Santa Cruz). 
3. Results and discussion 
A panel of human cell lines was analysed by Northern 
analysis in order to monitor SAP-I, ELK and SRF expres- 
sion. 
A major ubiquitous transcript of approx. 4.5 kb was de- 
tected with the SRF probe in all cell lines tested (Fig. 1); 
identically high levels were observed in all samples. These 
results stand in contrast with data reported by Norman et 
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Fig. 1. SFR mRNA levels in various cell lines. 30 lag of total RNA 
from Ramos (lane 1), BL2 (lane 2), E418 (lane 3), IARC-EWl7 
(lane 4), Saos (lane 5), HeLa (lane 6), Jurkat (lane 7) and K562 
(lane 8) cell lines were subjected to Northern blot analysis. Upper 
part: hybradization with the SRF probe; lower part: hybridization 
of the same blot with the control probe (18S RNA). 
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Fig. 2. TCF mRNA levels in various cell lines. (A) 30 lag total 
RNA from K562 (lane 1), HeLa (lane 2), Jurkat (lane 3), IARC- 
EWl7 (lane 4), Saos (lane 5), BL2 (lane 6), Ramos (lane 7) and 
E418 (lane 8) cell lines were subjected to Northern blot analysis. 
Upper part: SAP-la mRNAs; lower part: control probe (18S 
RNA). (B) 30 gg of total RNA from HeLa (lane 1), BL2 (lane 2), 
Ramos (lane 3), K562 (lane 4), Jurkat (lane 5), FA18 (lane 6), Saos 
(lane 7) and IARC-EWl7 (lane 8) cell lines were subjected to 
Northern blot analysis. Upper part: ELK1 mRNAs; lower part: 
control probe (18S RNA). (C) 30 ~tg of total RNA from Ramos 
(lane 1), BL2 (lane 2), E418 (lane 3), IARC-EWl7 (lane 4), Saos 
(lane 5), HeLa (lane 6), Jurkat (lane 7) and K562 (lane 8) cell lines 
were subjected to Northern blot analysis. Upper part: FLI-1 
mRNAs; lower part: control probe (18S RNA). 
al. [15] who described two SRF mRNAs of 4.5 and 2.9 kb 
in HeLa cells. In their experiments, however, cells had been 
synchronized by serum deprivation and subsequently acti- 
vated by growth factors, whereas we used exponentially grow- 
ing ceils. Thus, the 4.5 SRF transcript that we observed could 
be the major component of growing cells whereas the expres- 
sion of the 2.9 kb species could be restricted to a short period 
at the onset of the G1 phase. Indeed, the size of SRF tran- 
scripts could depend on the cell cycle, as suggested by data on 
terminal differentiation of myoblastic ell lines [16]. 
We next analysed TCF transcripts in the same cell lines: 
transcripts of approx. 1.8 and 3.1 kb were detected using a 
SAP- la probe (Fig. 2A) and an ELK-1 probe (Fig. 2B), re- 
spectively. These transcripts were detected in all cell lines 
tested, suggesting that they are ubiquitously expressed. In 
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Fig. 3. Ratio between ELK-1 and SAP-la mRNA levels in various 
cell lines. Hybridization to the SAP-la and ELK-1 mRNAs was 
quantified on a Bas 1000 phosphoimager and standardized by refer- 
ence to the 18S control probe. The ratio between ELK-1 and SAP- 
la RNA expression level for each cell line is shown, 
contrast, FLI-1, a member of the ETS family of DNA binding 
proteins known to be tissue-specific, was detected only in the 
four lymphocytic ell lines (Ramos, BL2, E418 and Jurkat), 
and not in K562, Hela, or Saos cells (Fig. 2C), Note that a 
faint band corresponding to the EWS-FLI1 fusion transcript 
of approx. 3.1 kb (vs. the normal 3.0 kb transcript FLI-1) is 
observed in the IARC-EW17 cell line, as expected for a cell 
line derived from a Ewing's sarcoma [26,27]. 
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Taken together, our data suggest that, in contrast to FLI-1, 
SAP-la and ELK-1 are ubiquitously expressed. However, 
SAP-la and ELK-1 mRNA levels were less homogeneous 
than SRF mRNA levels. Heterogeneity of cell lines with re- 
gard to TCF mRNA expression was confirmed by quantifica- 
tion of the Northern blot signals on a Bas 1000 Phosphoima- 
ger using an 18S probe as an internal reference. Fig. 3 shows 
the ratio between ELK-1 and SAP-1 RNA levels for each cell 
line. For example, HeLa cells were among the cell lines which 
expressed the highest level of ELK-1 mRNA, but low levels of 
SAP-1 (in agreement with data at the protein level from Pin- 
goud et al. [20]). 
In thus appears that expression of SAP-la and ELK-1 may 
be differentially controlled, whereas SRF is expressed at simi- 
lar levels in all cell lines tested. 
In order to verify these results, we have used Western blot 
analysis to study the expression of these genes at the protein 
level. SRF was detected at similar levels in all the cell lines, 
except for Jurkat, which expressed slightly higher levels of 
SRF (data not shown). We next used two antisera to detect 
SAP-1 and ELK-1 proteins, one of which crossreacts with 
both proteins (Fig. 4), the other being specific for ELK-1 
(data not shown). SAP-1 and ELK-1 proteins were also pres- 
ent in all cell lines tested but were expressed in a heterogenous 
manner, as detected with both antibodies. Again, the Jurkat 
and here also the Ramos cell lines expressed higher levels of 
both SAP-1 and ELK-1 when compared to the other cell lines. 
In order to standardize the quantitative analysis among all cell 
lines, we used the anti-SAP-1 antibody which also recognizes 
ELK-I (Fig. 4) for quantification, and the results were plotted 
as ratios between the signal intensity corresponding to ELK-1 
protein and that corresponding to SAP-la protein (Fig. 5). 
Ratios between ELK-1 and SAP-la protein levels were in 
agreement with the corresponding ratios at the RNA level, 
69KDa 
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Fig. 4. TCF levels in various cell lines. About 10 ~tg of nuclear protein extracts from HeLa (lane 3), Saos (lane 4), K562 (lane 5), E418 (lane 
6), BL2 (lane 7), IARC-EWl7 (lane 8), Jurkat (lane 9) and Ramos (lane 10) cell lines and equivalent amounts of in vitro translated ELK-1 
(lane 1) or SAP-la (lane 2) as controls, were subjected toWestern blot analysis, using an anti SAP-I/ELK-1 antiserum. 
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Fig. 5. Ratio between ELK-1 and SAP-la protein levels in various 
cell lines. Signals for both SAP-la and ELK-1 proteins, as revealed 
by Western blot analysis, were quantified (see Section 2). The ratio 
between ELK-1 and SAP-la protein expression level for each cell 
line is shown. 
including for the two cell lines (Jurkat and Ramos) showing a 
high absolute level of TCF proteins. HeLa cells, which 
showed the highest ratio between ELK-1 and SAP-la 
mRNA levels, also displayed the greatest ratio between 
ELK-1 and SAP-la at the protein level (Fig. 5). 
In order to confirm these observations, we next analysed 
the composition of ternary complexes formed in nuclear ex- 
tracts of some of these cell lines. EMSA was performed using 
specific and non-crossreacting anti-SAP-la or anti-ELK-1 
antibodies, which supershift the corresponding ternary com- 
plexes (Fig. 6A). Fig. 6B shows the results for two cell lines 
chosen for their high relative levels of expression of ELK- 
l(HeLa) or SAP-la (BL2). The results were consistent with 
data obtained by Western and Northern analyses. Ternary 
complexes in the HeLa nuclear extract were supershifted by 
anti-ELK-1 antibodies, whereas the anti-SAP-la ntibody did 
not have any effect. In contrast, in BL2 nuclear extracts, the 
ternary complex was supershifted only by the anti-SAP-la 
antibodies. 
Taken together these results confirm the hypothesis that 
different cells express different relative levels of the two 
TCFs, ELK-1 and SAP-I, thus raising the possibility that 
they may be regulated in a distinctive manner and may exert 
distinct function in cells. 
Indeed, two separate signalling pathways leading to modi- 
fication of different TCFs have been described: TCF/ELK-1 
would be a target for the Ras/MAP kinase pathway, whereas 
phosphorylated TCF/SAP-I complexes can be detected in the 
absence of MAP kinase activation [28]. Furthermore, SAP-1 
and ELK-1 have different patterns of sequence recognition 
0)Transactivation f c-los SRE through SAP-la in the absence of 
SRF. Masutani, H., Magnaghi-Jaulin, L., Groisman, R., Ait-SiAli, 
S., Robin, P. and Harel-Bellan, A. (submitted). 
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[29], and we have recently shown that SAP-la can transacti- 
vate the c-fos SRE in the absence of SRF, whereas ELK-1 
cannot (1). Therefore, it would not be surprising if SAP-1 and 
ELK-l, which seem to play distinct roles in the induction of 
immediate early genes, were found to be regulated ifferently. 
Interestingly, our data also suggest he existence of an in- 
verse correlation between the amounts of the two TCF related 
transcripts and proteins, SAP-la and ELK-l:  a high level of 
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Fig. 6. Analysis of the composition of ternary complexes in HeLa 
and BL2 nuclear extracts. (A) Control: equivalent amounts of in vi- 
tro translated SAP-la or ELK-1 proteins were analysed by EMSA 
in the presence of SRF, using either an anti-SAP-la or an anti- 
ELK-1 antibody as indicated; SRF+SAP-la (lane 1), SRF+SAP- 
la+anti-SAP-la (lane 2), SRF+ELK-1 (lane 3), SRF+ELK-I+anti- 
ELK-1 (lane 4). (B) In vitro translated SRF protein (lane 1), or 6 lag 
of nuclear extracts from HeLa cells (lanes 2-4) or BL2 cells (lanes 
5-7) were analysed by EMSA using either an anti-SAP-la (lanes 
3,6) or anti-ELK-1 (lanes 4,7) antibody. 
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one TFC was accompanied by low levels of the other, at both 
the RNA and protein levels, raising the possibility that SAP-1 
and ELK-1 could be expressed in a coordinated manner. 
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